医学
中枢性睡眠呼吸暂停
睡眠呼吸暂停
通风(建筑)
重症监护医学
呼吸暂停
物理医学与康复
多导睡眠图
急诊医学
心脏病学
麻醉
机械工程
工程类
作者
Michael Arzt,Oliver Munt,Raphaela Kübeck,Holger Woehrle,Raphaël Heinzer,Adam Benjafield,Jean‐Louis Pépin
出处
期刊:Annals of the American Thoracic Society
[American Thoracic Society]
日期:2025-05-13
卷期号:22 (10): 1546-1553
被引量:2
标识
DOI:10.1513/annalsats.202502-210oc
摘要
Abstract Rationale Treatment-emergent central sleep apnea (TE-CSA) is the most common indication for adaptive servo-ventilation (ASV). Evidence on the effects of TE-CSA treatment on quality of life (QoL) is limited. Objectives To test the hypotheses that patients with TE-CSA who have cardiovascular disease (CVD) would be less symptomatic than those with CVD and that the beneficial effects of ASV on QoL/sleepiness might be smaller in individuals with versus without CVD. Methods ASV-naive adults with TE-CSA and an ASV prescription were included in this analysis of the READ-ASV (Registry on the Treatment of Central and Complex Sleep-Disordered Breathing with ASV). QoL (Functional Outcomes of Sleep Questionnaire [FOSQ]) and daytime sleepiness (Epworth Sleepiness Scale [ESS]) were assessed at baseline and 12-month follow up. Results Of 452 patients with TE-CSA, 81% had CVD. Before treatment initiation, FOSQ and ESS scores were better in those with versus without CVD. On ASV, in the CVD and no CVD subgroups, median (interquartile range) FOSQ score significantly increased (+0.72 [–0.20 to +1.98], P < 0.001 and +0.90 [–0.12 to +2.29], P < 0.001, respectively), and the ESS score significantly decreased (–2.00 [–5.00 to 0.00], P < 0.001 and –3.00 [–6.75 to 0.00], P < 0.001); improvement magnitude was similar in both subgroups (P = 0.454 and P = 0.120). Conclusions The majority of individuals with TE-CSA and an ASV therapy prescription had CVD. Although those with TE-CSA and CVD were less symptomatic than those without CVD, ASV had a positive effect on QoL and sleepiness in these individuals, as well as those without CVD. Clinical trial registered with www.clinicaltrials.gov (NCT 03032029).
科研通智能强力驱动
Strongly Powered by AbleSci AI